EXCLUSIVE: Hoth Therapeutics Chief Scientific Officer, Stefanie Johns Now Interviewing On Benzinga’s Power Hour Show
Click To Tune In Here...https://www.youtube.com/watch?v=ZKRLWaZjDDw
EXCLUSIVE: Hoth Reports Safety Data From Early-Stage Study Of BioLexa Platform In Eczema
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma engaged in the development of therapies for unmet need, releases positive early-stage data for its BioLexa platform.
EXCLUSIVE: Hoth Therapeutics Announces Results In Cohort 1 Of Human Clinical Trial Of BioLexa In Eczema; Says No Serious Adverse Events And No Drug-Related Treatment-Emergent Adverse Events Observed
NEW YORK, NY, September 8, 2021 /PRNewswire/ Today, Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical
Hoth 8-K Shows Co. Disclosed Research Sponsored By Co. On Variants Of Sars-CoV-2 Virus Published In ‘Microbiology Spectrum’
On August 26, 2021, the Company disclosed that research sponsored by the Company on the variants of the Sars-CoV-2 virus was published in the journal Microbiology Spectrum. The article can be found at:
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)